Press Release: Change in the Supervisory Board at aap Implantate AG

aap Implantate AG / Change in the Supervisory Board at aap Implantate AG . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap") announces that Ronald Meersschaert will resign from his office as a member of the Supervisory Board for personal reasons. His duties will conclude on 5 October 2016. Ronald Meersschaert was first elected as a member of aap's Supervisory Board by the annual general meeting in financial year 2009. His successor will be Ms. Jacqueline Rijsdijk (60), who was elected as a substitute member for Mr. Meersschaert. Jacqueline Rijsdijk is a Board Advisor in the Netherlands and member of several Supervisory Boards and control committees of reputable companies such as Deloitte Netherlands and Royal Cosun.

Biense Visser, Chairman of the Supervisory Board at aap

, praises the work of Ronald Meersschaert over the past years: "We thank Ronald Meersschaert for his great commitment and the outstanding work for aap

on the way to a focused trauma company in recent years. As a recognised financial expert and seasoned investor, he was always a competent and trusted contact for the Supervisory and Management Boards and made a significant contribution in both financial and strategic matters."

In addition Biense Visser welcomes Jacqueline Rijsdijk's acceptance of the Supervisory Board mandate: "Jacqueline Rijsdijk is a regarded Board Advisor with comprehensive economic and financial knowledge and an excellent network. We are very much looking forward to our cooperation and are sure that aap

will benefit from her distinctive financial expertise and many years of experience."

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   September 12, 2016 06:02 ET (10:02 GMT)- - 06 02 AM EDT 09-12-16